Cytosorbents Corporation
CTSO
$1.13
$0.000.00%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -5.10% | 1.11% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.10% | 1.11% | |||
| Cost of Revenue | 21.14% | 5.48% | |||
| Gross Profit | -18.78% | -1.03% | |||
| SG&A Expenses | -5.53% | -11.15% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.53% | -10.76% | |||
| Operating Income | -33.97% | 34.35% | |||
| Income Before Tax | 43.66% | 34.84% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 43.66% | 34.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 43.66% | 34.84% | |||
| EBIT | -33.97% | 34.35% | |||
| EBITDA | -39.40% | 37.43% | |||
| EPS Basic | 43.77% | 34.90% | |||
| Normalized Basic EPS | 42.76% | 37.70% | |||
| EPS Diluted | 43.77% | 34.90% | |||
| Normalized Diluted EPS | 42.76% | 37.70% | |||
| Average Basic Shares Outstanding | 0.27% | 0.08% | |||
| Average Diluted Shares Outstanding | 0.27% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
